Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
kalkinemedia3h
Bristol-Myers Squibb (NYSE:BMY) Reports Robust Quarterly Earnings
Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...
bovnews5h
Bristol-Myers Squibb Co (BMY) Stock: Greater Than Its Current Valuation?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
US pharma major Eli Lilly to set up GCC in Hyd
Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...
PharmiWeb10h
Medidata Signs Multi-Year Agreement with Bristol Myers Squibb to Extend Relationship and Continue Company’s Use of Platform
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers ...
C&EN2h
50 new drugs received FDA approval in 2024
The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...
equities4h
Diabetes health impact fund T1D appoints Elizabeth Mily as CEO
The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday ...
Bristol Myers price target raised to $65 from $62 at Truist
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...